Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

The US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100mg/mL for the treatment of diabetic ...

The ranibizumab injection delivered through an implant device could be administered in a convenient schedule twice per year ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

WATERTOWN, Mass. - EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT), currently valued at $535 million, announced positive results from the Phase 2 VERONA clinical trial of DURAVYU™, its ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...

Susvimo is now available to U.S. retina specialists and their patients with DME. "Susvimo presents a unique, convenient treatment alternative to routine eye injections for people with a ...